Havey Adam
Known title: EVP, Business OperationsCIK: 0001514588
Associated companies
Transaction History
| EBS | ▲ Buy | Grant | 49,231 | $0 | 6/9/2023 | View on chart |
| EBS | ▲ Buy | Grant | 24,616 | $0 | 6/9/2023 | View on chart |
| EBS | ▲ Buy | Grant | 6,154 | $0 | 3/2/2023 | View on chart |
| EBS | ▲ Buy | Grant | 12,308 | $0 | 3/2/2023 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 998 | $12K | 2/28/2023 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 812 | $11K | 2/24/2023 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 432 | $6K | 2/23/2023 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 1,964 | $26K | 2/8/2023 | View on chart |
| EBS | ▲ Buy | Grant | 95 | $0 | 2/8/2023 | View on chart |
| EBS | ▲ Buy | Grant | 32,323 | $0 | 3/1/2022 | View on chart |
| EBS | ▲ Buy | Grant | 17,822 | $0 | 3/1/2022 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 739 | $29K | 2/28/2022 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 828 | $35K | 2/24/2022 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 424 | $18K | 2/23/2022 | View on chart |
| EBS | ▲ Buy | Grant | 1,836 | $0 | 2/22/2022 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 1,980 | $84K | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
EBS Shares Rise 14.4% After Russia Plague Lab Worker Death
EBS stock jumped 14.4% following the death of a Russian plague laboratory worker, a move that also lifted other vaccine makers such as Novavax, Arcturus and Moderna. The rally has drawn attention from retail traders who are looking for potential contract awards. The shares are currently trading near the $7.98 support level, which has been tested 20 times, and the RSI sits at 55.1, indicating neither overbought nor oversold conditions.
EBS Shares Rise 14.4% After Russia Plague Lab Worker Death. EBS stock jumped 14.4% following the death of a Russian plague laboratory worker, a move that also lifted other vaccine makers such as Novavax, Arcturus and Moderna. The rally has drawn attention from retail traders who are looking for potential contract awards. The shares are currently trading near the $7.98 support level, which has been tested 20 times, and the RSI sits at 55.1, indicating neither overbought nor oversold conditions.